VACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
NATIONAL INSTITUTES OF HEALTH NIAID
Contract Value
Not provided
Codes & Classification
Solicitation Number
75N98026D00088
NAICS
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Classification Code
AN12
Additional Details
The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), has issued an award notice for an Indefinite Delivery/Indefinite Quantity (IDIQ) contract focused on vaccine and other biologic manufacturing services for infectious diseases. This procurement activity is designed to support the federal government’s ongoing efforts in research and development related to infectious disease prevention and response, with a particular emphasis on the manufacturing of vaccines and biologic products.
The scope of this contract encompasses the provision of specialized manufacturing services necessary for the development and production of vaccines and other biologics targeting infectious diseases. The intended outcomes include ensuring the availability of high-quality manufacturing capabilities to support NIAID’s research initiatives and public health objectives. The contract is structured as an IDIQ, providing flexibility for the NIH to issue task orders as needs arise, with a guaranteed minimum award amount of $10,000.
Key requirements for this opportunity include demonstrated expertise in research and development within the physical, engineering, and life sciences fields, as classified under NAICS code 541715. While this code covers a broad range of R&D activities, it specifically excludes nanotechnology and biotechnology, indicating a focus on traditional and applied sciences relevant to vaccine and biologic manufacturing. Contractors are expected to deliver comprehensive manufacturing services that meet rigorous federal standards for quality, safety, and efficacy.
The place of performance for this contract is Washington, District of Columbia, aligning with the location of the NIH’s central operations. The contract falls under Product Service Code AN12, which pertains to R&D in health-related fields, further emphasizing the biomedical and public health focus of the work.
This procurement is managed by the NIH NIAID Office, a federal entity under the Department of Health and Human Services. The primary point of contact for this opportunity is Hamed Hassanzadeh Makou, who can be reached at [email protected] or by phone at 301-761-7466 for further information.
The notice is currently active and was posted on July 10, 2026. Contractors interested in this opportunity should review the official notice on SAM.gov (Opportunity ID: 081bfa13a5d54ca88920ee27f9eda478) for additional details and updates. No set-aside requirements or special considerations are specified in the provided information.
Overall, this contract represents a significant opportunity for organizations with capabilities in vaccine and biologic manufacturing to support critical federal research and public health initiatives in the field of infectious diseases.